• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc. (Amendment)

    2/14/23 4:15:33 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FULC alert in real time by email
    SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #1
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.

    Securities and Exchange Commission, Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

    (Name of Issuer)

    Fulcrum Therapeutics, Inc.

    (Title of Class of Securities)

    Common Stock, par value $0.001 per share

    (CUSIP Number)

    359616109

    (Date of Event Which Requires Filing of this Statement)

    December 31, 2022

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:

    [  ] Rule 13d-1(b)

    [ x ] Rule 13d-1(c)

    [  ] Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).


    CUSIP No. 359616109
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0
     
    (9) Aggregate amount beneficially owned by each reporting person
    0
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0%
     
    (12) Type of reporting person (see instructions) PN
     



    CUSIP No. 359616109
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0
     
    (9) Aggregate amount beneficially owned by each reporting person
    0
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0%
     
    (12) Type of reporting person (see instructions) CO
     



    CUSIP No. 359616109
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              30,702
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       30,702
     
    (9) Aggregate amount beneficially owned by each reporting person
    30,702
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1%
     
    (12) Type of reporting person (see instructions) OO
     



    CUSIP No. 359616109
    (1) Names of reporting persons    Point72 Hong Kong Limited
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Hong Kong
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    0 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0%
     
    (12) Type of reporting person (see instructions) OO
     



    CUSIP No. 359616109
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              30,702
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       30,702
     
    (9) Aggregate amount beneficially owned by each reporting person
    30,702
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1%
     
    (12) Type of reporting person (see instructions) IN
     



    Item 1(a) Name of issuer:

    Fulcrum Therapeutics, Inc.

    Item 1(b) Address of issuer's principal executive offices:

    26 Landsdowne Street, Cambridge, Massachusetts 02139

    2(a) Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, par value $0.001 per share
    (“Shares”), of the Issuer held by an investment fund it manages; (ii)
    Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect
    to Shares held by an investment fund managed by Point72 Asset
    Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic
    Strategies”) with respect to Shares held by an investment fund it
    manages; (iv) Point72 Hong Kong Limited (“Point72 Hong Kong”) with respect to
    Shares held by an investment fund it manages; and (v) Steven A. Cohen
    (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset
    Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and
    Point72 Hong Kong.

    2(b) Address or principal business office or, if none, residence:

    The address of the principal business office of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902;
    (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY 10001; and (iii) Point72 Hong Kong
    is Suites 1102 – 1110, 11th Floor and 12th Floor, Chater House, 8 Connaught Road Central, Hong Kong.

    2(c) Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware
    corporation. Cubist Systematic Strategies is a Delaware limited liability company. Point72 Hong Kong is a
    Hong Kong limited liability company. Mr. Cohen is a United States citizen.

    2(d) Title of class of securities:

    Common Stock, par value $0.001 per share

    2(e) CUSIP Number:

    359616109

    Item 3.

    Not applicable

    Item 4. Ownership

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting
    Person hereto and is incorporated herein by reference for each Reporting Person.  Such information is as of the
    close of business on December 31, 2022.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, Point72
    Hong Kong, and Mr. Cohen own directly no Shares. Pursuant to an investment management
    agreement, Point72 Asset Management maintains investment and voting power with respect to
    the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general
    partner of Point72 Asset Management. Pursuant to an investment management
    agreement, Cubist Systematic Strategies maintains investment and voting power with respect to
    the securities held by an investment fund it manages. Pursuant to an investment management
    agreement, Point72 Hong Kong maintains investment and voting power with respect to the
    securities held by an investment fund it manages. Mr. Cohen controls each of Point72 Asset
    Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and
    Point72 Hong Kong.  The filing of this statement should not be construed as an admission that
    any of the foregoing persons or any reporting person is, for the purposes of Section 13 of the Act,
    the beneficial owner of the Shares reported herein.

    Item 5.  Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [X].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    See Item 2(a).

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.

    Not applicable

    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities
    referred to above were not acquired and are not held for the purpose of or with the effect
    of changing or influencing the control of the issuer of the securities and were not acquired
    and are not held in connection with or as a participant in any transaction having that
    purpose or effect.


    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.


    Dated: February 14, 2023


    POINT72 ASSET MANAGEMENT, L.P.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 CAPITAL ADVISORS, INC.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    CUBIST SYSTEMATIC STRATEGIES, LLC

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 HONG KONG LIMITED

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    STEVEN A. COHEN

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person
    Get the next $FULC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FULC

    DatePrice TargetRatingAnalyst
    1/12/2026$20.00Overweight
    Analyst
    11/24/2025Buy
    Truist
    7/29/2025$4.00 → $12.00Neutral → Buy
    H.C. Wainwright
    5/23/2025$12.00Market Perform → Outperform
    Leerink Partners
    5/15/2025$10.00Neutral → Overweight
    Cantor Fitzgerald
    9/13/2024$17.00 → $4.00Buy → Neutral
    H.C. Wainwright
    9/12/2024$15.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    9/12/2024$4.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $FULC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4). Fulcrum granted the new employee 70,000 options to purc

    2/6/26 4:30:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to three new employees. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4). Fulcrum granted the new employees 30,400 options to

    1/9/26 4:30:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of the presentation will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics' website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulc

    1/7/26 8:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    SEC Filings

    View All

    Fulcrum Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)

    1/12/26 8:18:27 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)

    12/10/25 9:36:53 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Fulcrum Therapeutics Inc.

    424B5 - Fulcrum Therapeutics, Inc. (0001680581) (Filer)

    12/10/25 9:34:32 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Fulcrum Therapeutics with a new price target

    Analyst initiated coverage of Fulcrum Therapeutics with a rating of Overweight and set a new price target of $20.00

    1/12/26 8:13:43 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Fulcrum Therapeutics

    Truist initiated coverage of Fulcrum Therapeutics with a rating of Buy

    11/24/25 8:30:36 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Fulcrum Therapeutics from Neutral to Buy and set a new price target of $12.00 from $4.00 previously

    7/29/25 11:36:07 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sapir Alex bought $492,028 worth of shares (43,360 units at $11.35) (SEC Form 4)

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    3/5/24 4:15:17 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Gould Robert J sold $163,089 worth of shares (15,000 units at $10.87), decreasing direct ownership by 3% to 469,864 units (SEC Form 4)

    4/A - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    2/4/26 4:15:06 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Musso Alan A

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    2/4/26 4:10:05 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Principal Accounting Officer Tourangeau Greg

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    2/4/26 4:10:03 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Leadership Updates

    Live Leadership Updates

    View All

    Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

    CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Isabel Kalofonos as chief commercial officer and Heather Faulds as chief regulatory affairs & quality assurance officer. Together, Ms. Kalofonos and Ms. Faulds will be instrumental in advancing losmapimod towards a New Drug Application (NDA) submission and preparing for commercial launch. "I am excited to welcome Isabel to our leadership team as we continue to advance towards the potential approval a

    8/19/24 7:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

    ―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ― ― Interim Chief Medical Officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum's executive leadership team as senior vice president (SVP) of early development ― CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Patrick Horn, M.D., Ph.D., as

    3/18/24 7:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Appoints Chief Financial Officer

    CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Alan A. Musso as chief financial officer, effective August 7, 2023. A 30-year veteran in the life sciences industry, Mr. Musso has held numerous financial and operational leadership positions over the course of his career. "We are delighted to welcome Alan to our executive leadership team," said Alex C. Sapir, president and chief executive officer at Fulcrum Therapeutics. "Alan's wealth of industry experience and impressive track record

    8/3/23 6:55:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Financials

    Live finance-specific insights

    View All

    Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

    CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2025 financial results will be released on Wednesday, October 29, 2025, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details

    10/22/25 8:54:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    ― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― Evidence of pan-cellular induction of HbF based on an increase in F-cells (red blood cells containing HbF) from a mean of 34% at baseline to 67% at 12 weeks of treatment ― ― Meaningful improvements in key markers of hemolysis coupled with a 0.9 g/dL mean increase in total hemoglobin (Hb) ― ― Encouraging trends in vaso-occlusive crisis (VOC) reduction compared to baseline ― ― Pociredir continued to be generally well-tolerated with no treatment-related serious adverse events (SAEs); all treatment

    7/29/25 6:45:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, July 29, 2025 beginning at 8:00 a.m. ET to present topline results from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum management will be joined by Dr. Sheinei Alan, Director of the Inova Fairfax Adult Sickle Cell Program, and Assistant Professor at UVA School of Medicine Inova Campus, and Dr. Wally Smith, Director at the VC

    7/28/25 4:01:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/14/24 4:25:46 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/14/24 6:15:07 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/12/24 3:51:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care